Skip to main content

Advertisement

Table 2 Relationship between elevation in liver enzyme concentration and patient characteristics at baseline by treatment regimen

From: Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

  Peak ALT or AST
≥3 × ULN1
  Standard arm
(2EHRZ/4HR)
Isoniazid arm
(2MHRZ/2MHR)
Ethambutol arm
(2EMRZ/2MR)
n (%) 60 / 639 (9.4%) 52 / 654 (8.0%) 38 / 634 (6.0%)
Male (%) 40 / 447 (9.0%) 38 / 449 (8.5%) 24 / 447 (5.4%)
Female (%) 20 / 192 (10.4%) 14 / 205 (6.8%) 14 / 188 (7.5%)
Age in years2 (%)
 18–24 13 / 186 (7.0%) 17 / 203 (8.4%) 11 / 172 (6.4%)
 25–34 21 / 184 (11.4%) 11 / 213 (5.2%) 9 / 210 (4.3%)
 35–44 16 / 142 (11.3%) 11 / 115 (9.6%) 8 / 122 (6.6%)
 45–54 2 / 88 (2.3%) 6 / 81 (7.4%) 8 / 86 (9.3%)
 ≥55 8 / 38 (21.1%) 7 / 41 (17.1%) 2 / 44 (4.6%)
Baseline weight in kg (%)
 <40 11 /63 (17.5%) 6 / 56 (10.7%) 5 / 56 (8.9%)
 40–49 22 / 218 (10.1%) 20 / 243 (8.2%) 11 / 224 (4.9%)
 50–59 16 / 242 (6.6%) 19 / 231 (8.2%) 12 / 236 (5.1%)
 60–69 8 / 88 (9.1%) 5 / 88 (5.7%) 8 / 86 (9.3%)
 ≥70 3 / 28 (10.7%) 2 / 36 (5.6%) 2 / 33 (6.1%)
Ethnicity (%)
 Black 20 / 295 (6.8%) 21 / 277 (7.6%) 17 / 290 (5.9%)
 Asian 34 / 194 (17.5%) 23 / 201 (11.4%) 10 / 193 (5.18%)
 Mixed race 6 /149 (4.0%) 8 / 174 (4.6%) 11 / 151 (7.3%)
 Other 0 / 1 (0.0%) 0 / 2 (0.0%) 0 / 0 (0.0%)
HIV positive (%) 7 / 46 (15.2%) 3 / 46 (6.5%) 4 / 48 (8.3%)
HIV negative (%) 53 / 593 (8.9%) 49 / 608 (8.1%) 34 / 586 (5.8%)
Smoking history (%)
 Never 31 / 298 (10.4%) 23 / 291 (7.9%) 16 / 279 (5.7%)
 Previous 11 / 155 (7.1%) 17 / 155 (11.0%) 9 / 166 (5.4%)
 Current 18 / 186 (9.7%) 12 / 208 (5.8%) 13 / 190 (6.8%)
  1. Characteristics for patients across all treatment arms are shown according to peak ALT and/or AST while taking treatment
  2. ALT alanine aminotransferase, AST aspartate aminotransferase, ULN upper limit of normal
  3. 1 Cell percentages shown
  4. 2 Data for date of birth was not available for some patients in all three treatment arms